Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Large Cell Neuroendocrine Carcinoma · Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) · Small Cell Lung Cancer (SCLC) · Gastroenteropancreatic NEC (GEP NEC) · NEC of the Bladder · Other DLL3 Expressing epNEC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Emory University Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (Ryan Hanula) · rhanula@emory.edu · 404-778-5141
United Theranostics, Glen Burnie, Maryland, United States
Contact: Study coordinator (Amanda Huggins) · clinicaltrial@unithera.com · 667-HOPENOW
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Contact: Study coordinator (Research Director) · clinicaltrials@nebraskacancer.com · 402-955-2691
United Theranostics, Princeton, New Jersey, United States
Contact: Study coordinator (Amanda Huggins) · clinicaltrial@unithera.com · 667-HOPENOW
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Contact: Study coordinator (Dr A.Dowlati) · afshin.dowlati@uhhospitals.org · 216-368-1122

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Neuroendocrine Carcinoma

Abroad (travel likely)RecruitingPHASE3

Angers, France · Avignon, France

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Small Cell Lung Cancer (SCLC) · Large Cell Neuroendocrine Cancer (LCNEC) · Neuroendocrine Prostate Cancer (NEPC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Los Angeles, United States

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Anchorage, United States

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Melanoma · Medullary Thyroid Cancer · Sinonasal Undifferentiated Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tucson, United States · Seattle, United States